Track market-moving stories before they get noisy

Nice (NICE - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Over the past month, shares of this software company have returned -19.9%, compared to the Zacks S&P 500 composite's +6.3% change. During this period, the Zacks Internet - Software industry, which Nice falls in, has gained 9%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

Nice is expected to post earnings of $2.63 per share for the current quarter, representing a year-over-year change of -12.6%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.4%.

For the current fiscal year, the consensus earnings estimate of $11.1 points to a change of -9.8% from the prior year. Over the last 30 days, this estimate has changed +2.1%.

For the next fiscal year, the consensus earnings estimate of $12.64 indicates a change of +13.9% from what Nice is expected to report a year ago. Over the past month, the estimate has changed +1.5%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Nice is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

For Nice, the consensus sales estimate for the current quarter of $767.17 million indicates a year-over-year change of +5.6%. For the current and next fiscal years, $3.18 billion and $3.49 billion estimates indicate +7.9% and +9.7% changes, respectively.

Last Reported Results and Surprise HistoryNice reported revenues of $768.62 million in the last reported quarter, representing a year-over-year change of +9.8%. EPS of $2.64 for the same period compares with $2.87 a year ago.

Compared to the Zacks Consensus Estimate of $761.09 million, the reported revenues represent a surprise of +0.99%. The EPS surprise was +4.76%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Nice is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Nice. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

HOBOKEN, N.J.--(BUSINESS WIRE)--NiCE (Nasdaq: NICE) today announced a fundamental shift in customer experience: with agentic AI native at the core of its platform, enterprises can now run AI agents, human teams, workflows, data, and systems as one intelligent operating model. For decades, customer experience meant routing interactions to people. NiCE changes that. AI now understands intent, resolves issues autonomously, engages customers proactively, orchestrates work across front- and back-off.

HOBOKEN, N.J.--(BUSINESS WIRE)--NiCE (Nasdaq: NICE) today announced NiCE Labs, the dedicated AI innovation lab established to conduct advanced research, rigorous benchmarking, and rapid prototyping at the leading edge of agentic customer experience. Unveiled at NiCE World in Orlando, NiCE Labs will operate as NiCE's incubation and innovation engine, bringing together the company's most advanced AI expertise and working in close collaboration with customers and partners to apply advanced AI rese.

NiCE (Nasdaq: NICE) today announced the winners of its 2026 CX Excellence Awards at NiCE World, recognizing the organizations leading the AI era of customer experience. This year’s honorees have moved beyond AI experimentation to embed AI deeply into how customer experience operates, scales, and improves. By orchestrating AI agents, human agents, workflows, and data as one coordinated intelligence layer, they are running a new operating model for CX, one that compounds intelligence with every interaction and delivers proven, measurable business outcomes at enterprise scale.

This year’s CX Excellence Award winners were recognized across the following categories:

Excellence in Engagement Orchestration: Consumer Cellular
Consumer Cellular, a leading wireless provider serving approximately 4.5 million subscribers, earned this recognition for its enterprise-wide AI deployment across 100% of its U.S.-based contact center agents. The company's rapid and seamless adoption transformed agent workflows in real time, enabling agents to remain fully focused on customer conversations while AI handles complexity in the background. Consumer Cellular's implementation stands as a benchmark for at-scale AI integration that enhances the human connection at the heart of every interaction.

Excellence in Workforce Empowerment: TD Bank
TD Bank was recognized for achieving record-breaking customer satisfaction results in fiscal 2025 under exceptional operating conditions, including a national postal strike, sustained volatility in its Wealth business, and historically lean staffing levels. Customer satisfaction reached an all-time high for the second consecutive year, while self-service scheduling grew 10% year over year through expanded automation and scheduling flexibility. TD Bank's results demonstrate how AI-powered workforce solutions can drive measurable performance gains even in the most demanding environments.

Excellence in Agentic Experience Automation: Fabletics
Fabletics, one of the world’s largest digitally native activewear brands, is redefining digital-first engagement through innovation and AI-powered customer journeys. Fabletics has deployed agentic AI voice at scale to support and enhance some of the most critical parts of the customer journey. The company’s approach to AI is centered on enhancing customer relationships while empowering teams to work smarter and more efficiently.

Excellence in AI Innovation: Arizona State University
Arizona State University was honored for its pioneering use of AI to proactively engage students at high-stakes moments across the academic journey. Rather than deploying AI solely as a reactive support tool, ASU uses it to reach students before critical deadlines pass, enabling resolution at the first interaction for the vast majority of engagements that previously required a call to the university's Experience Center. ASU's model represents a meaningful shift in how higher education institutions can apply AI to improve student outcomes at scale.

“This year’s winners are showing the world what leadership in the AI era of customer experience truly looks like,” said Dan Belanger, President, NiCE Americas. “They are using AI to create faster resolutions, more seamless journeys, stronger employee experiences, and better business outcomes at scale. They are turning every interaction into an opportunity to build smarter operations, deeper customer loyalty, and lasting competitive advantage.”

About NiCE
NiCE (NASDAQ: NICE) is transforming the world with AI that puts people first. Our purpose-built AI-powered platforms automate engagements into proactive, safe, intelligent actions, empowering individuals and organizations to innovate and act, from interaction to resolution. Trusted by organizations throughout 150+ countries worldwide, NiCE’s platforms are widely adopted across industries connecting people, systems, and workflows to work smarter at scale, elevating performance across the organization, delivering proven measurable outcomes.

Trademark Note: NiCE and the NiCE logo are trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE's marks, please see: www.nice.com/nice-trademarks.

Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including the statements by Mr. Belanger, are based on the current beliefs, expectations and assumptions of the management of NICE Ltd. (the “Company”). In some cases, such forward-looking statements can be identified by terms such as “believe,” “expect,” “seek,” “may,” “will,” “intend,” “should,” “project,” “anticipate,” “plan,” “estimate,” or similar words. Forward-looking statements are subject to a number of risks and uncertainties that could cause the actual results or performance of the Company to differ materially from those described herein, including but not limited to the impact of changes in general economic and business conditions; competition; successful execution of the Company’s growth strategy; success and growth of the Company’s cloud Software-as-a-Service business; rapid changes in technology and market requirements; the implementation of AI capabilities in certain products and services, decline in demand for the Company's products; inability to timely develop and introduce new technologies, products and applications; difficulties in making additional acquisitions or difficulties or effectively integrating acquired operations; loss of market share; an inability to maintain certain marketing and distribution arrangements; the Company’s dependency on third-party cloud computing platform providers, hosting facilities and service partners; cyber security attacks or other security incidents; privacy concerns; changes in currency exchange rates and interest rates, the effects of additional tax liabilities resulting from our global operations, the effect of unexpected events or geo-political conditions, including those arising from political instability or armed conflict that may disrupt our business and the global economy; our ability to recruit and retain qualified personnel; the effect of newly enacted or modified laws, regulation or standards on the Company and our products and various other factors and uncertainties discussed in our filings with the U.S. Securities and Exchange Commission (the “SEC”). For a more detailed description of the risk factors and uncertainties affecting the company, refer to the Company's reports filed from time to time with the SEC, including the Company’s Annual Report on Form 20-F. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no obligation to update or revise them, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260610731922/en/

1.41K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

MIAMI, April 02, 2026 (GLOBE NEWSWIRE) -- PennantPark Floating Rate Capital Ltd. (the "Company") (NYSE: PFLT) declares its monthly distribution for April 2026 of $0.1025 per share, payable on May 1, 2026 to stockholders of record as of April 15, 2026. The distribution is expected to be paid from taxable net investment income. The final specific tax characteristics of the distribution will be reported to stockholders on Form 1099 after the end of the calendar year and in the Company's periodic report filed with the Securities and Exchange Commission.

The Company, which operates as a regulated investment company (“RIC”), generates qualified interest income and short-term capital gains that may be exempt from U.S. withholding tax when distributed to non-U.S. stockholders. The U.S. tax law permits a RIC to report the portion of distributions paid that represents interest-related dividends as exempt from U.S. withholding tax when paid to non-U.S. stockholders with proper documentation.

The specific tax characteristics of this distribution can be found on our website www.pennantpark.com.

ABOUT PENNANTPARK FLOATING RATE CAPITAL LTD.

PennantPark Floating Rate Capital Ltd. is a business development company which primarily invests in U.S. middle-market private companies in the form of floating rate senior secured loans, including first lien secured debt, second lien secured debt and subordinated debt. From time to time, the Company may also invest in equity investments. PennantPark Floating Rate Capital Ltd. is managed by PennantPark Investment Advisers, LLC.

ABOUT PENNANTPARK INVESTMENT ADVISERS, LLC

PennantPark Investment Advisers, LLC, a leading middle market credit platform, and its affiliates, manage approximately $10 billion of investable capital, including potential leverage. Since its inception in 2007, PennantPark Investment Advisers, LLC has provided investors access to middle market credit by offering private equity firms and their portfolio companies as well as other middle-market borrowers a comprehensive range of creative and flexible financing solutions. PennantPark Investment Advisers, LLC is headquartered in Miami and has offices in New York, Chicago, Houston, Los Angeles, Amsterdam, and Zurich. For more information about PennantPark and affiliates, please go to our website at www.pennantpark.com.

FORWARD-LOOKING STATEMENTS

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. You should understand that under Section 27A(b)(2)(B) of the Securities Act and Section 21E(b)(2)(B) of the Exchange Act the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 do not apply to forward-looking statements made in periodic reports PennantPark Floating Rate Capital Ltd. files under the Exchange Act. All statements other than statements of historical facts included in this press release are forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in filings with the Securities and Exchange Commission. PennantPark Floating Rate Capital Ltd. undertakes no duty to update any forward-looking statement made herein. You should not place undue influence on such forward-looking statements as such statements speak only as of the date on which they are made.

The information contained herein is based on current tax laws, which may change in the future. The Company cannot be held responsible for any direct or incidental loss resulting from applying any of the information provided in this publication or from any other source mentioned. The information provided in this material does not constitute any specific legal, tax or accounting advice. Please consult with qualified professionals for this type of advice.

CONTACT:
Richard T. Allorto, Jr.
PennantPark Floating Rate Capital Ltd.
(212) 905-1000
www.pennantpark.com

MIAMI, April 06, 2026 (GLOBE NEWSWIRE) -- PennantPark Floating Rate Capital Ltd. (the "Company") (NYSE: PFLT) announced that it will report results for the second fiscal quarter ended March 31, 2026 on Thursday, May 7, 2026 after the close of the financial markets.

The Company will also host a conference call at 9:00 a.m. (Eastern Time) on Friday, May 8, 2026 to discuss its financial results. All interested parties are welcome to participate. You can access the conference call by dialing toll-free (800) 330-6710 approximately 5-10 minutes prior to the call. International callers should dial (646) 769-9200. All callers should reference conference ID #9559786 or PennantPark Floating Rate Capital Ltd. An archived replay will also be available on a webcast link located on the Quarterly Earnings page in the Investor section of PennantPark’s website.

ABOUT PENNANTPARK FLOATING RATE CAPITAL LTD.

PennantPark Floating Rate Capital Ltd. is a business development company which primarily invests in U.S. middle-market private companies in the form of floating rate senior secured loans, including first lien secured debt, second lien secured debt and subordinated debt. From time to time, the Company may also invest in equity investments. PennantPark Floating Rate Capital Ltd. is managed by PennantPark Investment Advisers, LLC.

ABOUT PENNANTPARK INVESTMENT ADVISERS, LLC

PennantPark Investment Advisers, LLC is a leading middle market credit platform, and its affiliates, manage approximately $10 billion of investable capital, including potential leverage. Since its inception in 2007, PennantPark Investment Advisers, LLC has provided investors access to middle market credit by offering private equity firms and their portfolio companies as well as other middle-market borrowers a comprehensive range of creative and flexible financing solutions. PennantPark Investment Advisers, LLC is headquartered in Miami and has offices in New York, Chicago, Houston, Los Angeles, Amsterdam and Zurich. For more information about PennantPark and affiliates, please go to our website at www.pennantpark.com.

FORWARD-LOOKING STATEMENTS

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included in this press release are forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in filings with the Securities and Exchange Commission. PennantPark Floating Rate Capital Ltd. undertakes no duty to update any forward-looking statement made herein. You should not place undue influence on such forward-looking statements as such statements speak only as of the date on which they are made.

CONTACT:

Richard T. Allorto, Jr.
PennantPark Floating Rate Capital Ltd.
(212) 905-1000
www.pennantpark.com

Investors in PennantPark Floating Rate Capital Ltd. (PFLT - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the May 15, 2026 $40 Call had some of the highest implied volatility of all equity options today.

What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

What do the Analysts Think?Clearly, options traders are pricing in a big move for PennantPark shares, but what is the fundamental picture for the company? Currently, PennantPark is a Zacks Rank #4 (Sell) in the Financial - Investment Management industry that ranks in the Bottom 14% of our Zacks Industry Rank. Over the last 60 days, one analyst has increased the earnings estimates for the current quarter, while none dropped the estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from 29 cents per share to 28 cents in that period.

Given the way analysts feel about PennantPark right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.

© Jack_the_sparow / Shutterstock.com

Income investors holding PennantPark Floating Rate Capital (NYSE:PFLT) face a direct question: can a business development company that has under-earned its distribution for four straight quarters keep paying $0.1025 a month? The data points in two directions, and the answer hinges largely on a single joint venture.

PFLT is a BDC that functions as a packaged income vehicle for investors seeking exposure to direct middle-market lending. The fund earns interest on a $2.54 billion portfolio of senior secured loans to companies with $10 to $50 million in EBITDA. Roughly 99% of the debt book carries floating rates, and 89% sits in first-lien positions, giving lenders the senior claim on collateral if a borrower defaults.

The Four-Quarter Coverage Gap Core net investment income came in at $0.27 in Q1 FY26 against a $0.31 quarterly distribution, missing the $0.30 consensus by 10%. That marks the fourth straight quarter of under-coverage, following $0.28 in Q4 FY25, $0.27 in Q3, and $0.28 in Q2. Total investment income grew to $70.1 million, but yield compression and share dilution squeezed the per-share math.

The weighted average yield on debt investments slid from 11.5% a year ago to 10.2% sequentially to 9.9% in the latest quarter. The Federal Reserve’s 75 basis points of cuts since September, taking the upper bound to 3.75%, flow through PFLT’s floating-rate book. Cost of debt improved to 6.2% from 7.0%, but not fast enough to close the gap.

First-Lien Armor and a $0.25 Buffer The credit story is the bull case. PIK interest accounts for just 2.5% of total interest income, among the lowest in the BDC industry, meaning borrowers pay actual cash rather than rolling interest into principal. Median portfolio leverage runs 4.5x EBITDA with 2.1x interest coverage. CEO Art Penn argues these loans carry “meaningful covenants that safeguard our capital”, in contrast to the covenant-light upper market.

Loss history reinforces that. Across $8.7 billion deployed into 545 companies over 14 years, PFLT reports an annual loss ratio of 13 basis points. Non-accruals have risen to 4 investments, or 0.5% of cost, but remain modest. Management holds a $0.25 per share spillover income buffer that can backstop the distribution if NII falls short.

The PSSL II Lifeline Closing the coverage gap depends on PennantPark Senior Secured Loan Fund II, a Hamilton Lane joint venture in which PFLT owns 75%. PSSL II reached $326 million in assets after the latest quarter and upsized its credit facility to $250 million. Penn told investors PSSL II must scale toward $1 billion for the math to work, with a timeline of 12 to 24 months: “It’s not gonna be next quarter. But we’re off to a good start.”

NAV Erosion and Total Return Book value tells the cautionary side. NAV per share fell from $11.31 at FY24 year-end to $10.49 after Q1 FY26, with net unrealized depreciation widening to $78.4 million from $11.4 million a year and a half earlier. Management attributes most markdowns to a 2021 post-COVID vintage in consumer retail and logistics names like Pink Lily and Dynata.

Shares trade near $9, up about 3% year to date and about 4% over one year. Including distributions, total return remains positive, but the price trails NAV, signaling market skepticism about coverage.

The Verdict The dividend is at risk but not broken. PFLT’s first-lien collateral, low PIK exposure, spillover buffer, and floating-rate insulation give management real time to bridge the gap through PSSL II. The risk is that yield compression continues, non-accruals climb, and the joint venture scales slower than 18 months. PFLT suits investors comfortable with BDC credit risk and a credible turnaround thesis. Investors who need certain coverage today may prefer to see NII catch the distribution before committing capital.

MIAMI, May 07, 2026 (GLOBE NEWSWIRE) -- PennantPark Floating Rate Capital Ltd. (NYSE: PFLT) announced today its financial results for the second quarter ended March 31, 2026.

    HIGHLIGHTS
Quarter ended March 31, 2026 (Unaudited)
($ in millions, except per share amounts)       Assets and Liabilities:   Investment portfolio (1)(2)$2,580.3 Net assets$1,038.7 Net asset value per share$10.47 Quarterly change in net asset value per share (0.2)%  Credit Facility$328.3 2026 Notes, net of unamortized deferred financing costs$185.0 2029 Notes, net of unamortized deferred financing costs$195.9 2036-R Asset-Backed Debt, net of unamortized deferred financing costs$286.6 2037 Asset-Backed Debt, net of unamortized deferred financing costs$387.1 2038-R Asset-Backed Debt, net of unamortized deferred financing costs$284.8 Debt to equity 1.61x Weighted average yield on debt investments at quarter-end 9.8%    Operating Results:
   Net investment income$25.7 Net investment income per share (GAAP)$0.26 Core net investment income per share (3)$0.27 Distributions declared per share$0.31     Portfolio Activity   Purchases of Investments  294.8 Sales and repayments of investments  328.0     PSSL Portfolio data:   PSSL investment portfolio$1,209.0 Purchases of investments$58.6 Sales and repayments of investments$32.2     PSSL II Portfolio data:   PSSL II investment portfolio$339.9 Purchases of investments$148.1 Sales and repayments of investments$1.3  ________________________

(1) Includes investments in PennantPark Senior Secured Loan Fund I LLC, or PSSL, an unconsolidated joint venture, totaling $297.8 million, at fair value.(2) Includes investments in PennatPark Senior Secured Loan Fund II LLC, or PSSL II, an unconsolidated joint venture, totaling $93.5 million, at fair value.(3) Core net investment income (“Core NII”) is a non-GAAP financial measure. The Company believes that Core NII provides useful information to investors and management because it reflects the Company's financial performance excluding one-time or non-recurring investment income and expenses. The presentation of this additional information is not meant to be considered in isolation or as a substitute for financial results prepared in accordance with GAAP. For the quarter ended March 31, 2026, Core NII excluded: i) $1.1 million of debt issuance costs and ii) $0.2 million of incentive fee expense offset.    CONFERENCE CALL AT 9:00 A.M. ET ON MAY 8, 2026

The Company will also host a conference call at 9:00 a.m. (Eastern Time) on Friday, May 8, 2026 to discuss its financial results. All interested parties are welcome to participate. You can access the conference call by dialing toll-free (800) 330-6710 approximately 5-10 minutes prior to the call. International callers should dial (646) 769-9200. All callers should reference conference ID #9559786 or PennantPark Floating Rate Capital Ltd. An archived replay will also be available on a webcast link located on the Quarterly Earnings page in the Investor section of PennantPark’s website.

PORTFOLIO AND INVESTMENT ACTIVITY

“We are pleased with the continued quality and performance of our investment portfolio in this market. The risk-reward of the core middle market remains differentiated from the upper middle market. Despite the challenging market environment, NAV was flat for the quarter and portfolio company leverage, PIK interest and non accruals are among the lowest in the industry. The substantial growth of the PSSL II JV this past quarter provides a solid base and positions PFLT for growth in NII over time as the JV ramps" said Art Penn, Chairman and CEO. "Given the lower interest rate environment and current market activity levels, in consultation with the Board, we will be adjusting our dividend policy to be better aligned with NII, starting with the July dividend."

As of March 31, 2026, our portfolio totaled $2,580.3 million, and consisted of $2,252.1 million of first lien secured debt (including $237.7 million in PSSL and $65.6 million in PSSL II), $18.8 million of subordinated debt and $309.3 million of preferred and common equity (including $60.1 million in PSSL and $27.9 million in PSSL II). Our debt portfolio consisted of approximately 99% variable-rate investments. As of March 31, 2026, we had three portfolio companies on non-accrual, representing 0.8% and 0.5% of our overall portfolio on a cost and fair value basis, respectively. As of March 31, 2026, the portfolio had net unrealized depreciation of $66.1 million. Our overall portfolio consisted of 162 companies with an average investment size of $15.9 million and had a weighted average yield on debt investments of 9.8%.

As of September 30, 2025, our portfolio totaled $2,773.3 million and consisted of $2,513.6 million of first lien secured debt (including $237.7 million in PSSL), $19.0 million of second lien and subordinated debt and $240.7 million of preferred and common equity (including $44.3 million in PSSL). Our debt portfolio consisted of approximately 99% variable-rate investments. As of September 30, 2025, we had three portfolio companies on non-accrual, representing 0.4% and 0.2% of our overall portfolio on a cost and fair value basis, respectively. As of September 30, 2025, the portfolio had net unrealized depreciation of $46.1 million. Our overall portfolio consisted of 164 companies with an average investment size of $16.9 million, and a weighted average yield on debt investments of 10.2%.

For the three months ended March 31, 2026, we invested $294.8 million in six new and 53 existing portfolio companies at a weighted average yield on debt investments of 9.3%. Sales and repayments of investments for the same period totaled $328.0 million including $56.9 million of sales to PSSL and $148.1 million of sales to PSSL II. For the six months ended March 31, 2026, we invested $595.8 million in 10 new and 74 existing portfolio companies with a weighted average yield on debt investments of 9.6%. Sales and repayments of investments for the same period totaled $769.5 million including $189.4 million of sales to PSSL and $344.6 million of sales to PSSL II.

For the three months ended March 31, 2025, we invested $293.3 million in three new and 54 existing portfolio companies at a weighted average yield on debt investments of 9.9%. Sales and repayments of investments for the same period totaled $122.4 million including $52.9 million of sales to PSSL. For the six months ended March 31, 2025, we invested $900.2 million in 14 new and 96 existing portfolio companies with a weighted average yield on debt investments of 10.2%. Sales and repayments of investments for the same period totaled $523.7 million, including $240.6 million of sales to PSSL.

PennantPark Senior Secured Loan Fund I LLC

As of March 31, 2026, PSSL’s portfolio totaled $1,209.0 million, consisted of 120 companies with an average investment size of $10.1 million and had a weighted average yield on debt investments of 9.5%. As of September 30, 2025, PSSL’s portfolio totaled $1,084.6 million, consisted of 117 companies with an average investment size of $9.3 million and had a weighted average yield on debt investments of 10.1%.

For the three months ended March 31, 2026, PSSL invested $58.6 million (including $56.9 million purchase from the Company) in three new and five existing portfolio companies with a weighted average yield on debt investments of 9.2%. PSSL’s sales and repayments of investments for the same period totaled $32.2 million. For the six months ended March 31, 2026, PSSL invested $192.4 million (including $189.4 million purchase from the Company) in seven new and 22 existing portfolio companies with a weighted average yield on debt investments of 9.3%. PSSL's sales and repayments of investments for the same period totaled $44.6 million.

For the three months ended March 31, 2025, PSSL invested $60.0 million (including $52.9 million purchase from the Company) in four new and five existing portfolio companies with a weighted average yield on debt investments of 9.8%. PSSL’s sales and repayments of investments for the same period totaled $36.8 million. For the six months ended March 31, 2025, PSSL invested $284.9 million (including $240.6 million purchased from the Company) in 21 new and 12 existing portfolio companies with a weighted average yield on debt investments of 10.2%. PSSL’s sales and repayments of investments for the same period totaled $123.4 million.

PennantPark Senior Secured Loan Fund II LLC

As of March 31, 2026, PSSL II’s portfolio totaled $339.9 million and consisted of 54 companies with an average investment size of $6.3 million and at a weighted average yield on debt investments of 8.9%.

For the three months ended March 31, 2026, PSSL II invested $148.1 million (including $148.1 million purchased from the Company) in 12 new and 15 existing portfolio companies at a weighted average yield on debt investments of 8.8%. Sales and repayments of investments for the three months ended March 31, 2026 totaled $1.3 million. For the six months ended March 31, 2026, PSSL II invested $344.6 million (including $344.6 million purchased from the Company) in 54 new and zero existing portfolio companies at a weighted average yield on debt investments of 9.1%. Sales and repayments for the same period totaled $4.2 million.

RESULTS OF OPERATIONS

Set forth below are the results of operations for the three and six months ended March 31, 2026 and 2025.

Investment Income

For the three and six months ended March 31, 2026 investment income was $66.0 million and $136.0 million, respectively, which was attributable to $58.6 million and $122.9 million from first lien secured debt and $7.3 million and $13.2 million from other investments, respectively. For the three and six months ended March 31, 2025, investment income was $61.9 million and $128.9 million, respectively, which was attributable to $56.2 million and $117.2 million from first lien secured debt and $5.7 million and $11.7 million from other investments, respectively. The increase in investment income for the three and six months ended March 31, 2026, was primarily due to the increase in the size of our debt portfolio.

Expenses

For the three and six months ended March 31, 2026, expenses totaled $40.2 million and $83.7 million, respectively and were comprised of: $24.1 million and $51.3 million of debt related interest and expenses, $6.4 million and $13.2 million of base management fees, $6.4 million and $13.1 million of performance-based incentive fees, $2.1 million and $4.2 million of general and administrative expenses, less than $0.1 million and $0.3 million of taxes and $1.1 million and $1.6 million in Credit Facility amendment and debt issuance costs. For the three and six months ended March 31, 2025, expenses totaled $36.9 million and $74.0 million, respectively and were comprised of: $22.5 million and $44.9 million of debt related interest and expenses, $5.6 million and $10.9 million of base management fees, $6.3 million and $13.8 million of performance-based incentive fees, $1.9 million and $3.6 million of general and administrative expenses, $0.2 million and $0.5 million of taxes and $0.4 million and $0.4 million in Credit Facility amendment costs. The increase in expenses for the three and six months ended March 31, 2026, was primarily due to the increase in interest expense from increased borrowings as a result of the increase in our investment portfolio.

Net Investment Income

For the three and six months ended March 31, 2026 net investment income totaled $25.8 million or $0.26 per share, and $52.4 million or $0.53 per share, respectively. For the three and six months ended March 31, 2025 net investment income totaled $25.0 million or $0.28 per share, and $55.0 million or $0.64 per share, respectively. The decrease in net investment income for the six months ended March 31, 2026, was primarily due to an increase in interest expense and one time credit facility amendment and debt issuance costs.

Net Realized Gains or Losses

For the three and six months ended March 31, 2026 net realized gains (losses) totaled $(8.9) million and $(7.5) million, respectively. For the three and six months ended March 31, 2025 net realized gains (losses) totaled $(3.5) million and $23.1 million, respectively. The change in net realized gains (losses) was primarily due to changes in the market conditions of our investments and the values at which they were realized.

Unrealized Appreciation or Depreciation on Investments and Debt

For the three and six months ended March 31, 2026, we reported net change in unrealized appreciation (depreciation) on investments of $12.2 million and $(20.1) million, respectively. For the three and six months ended March 31, 2025 we reported net change in unrealized appreciation (depreciation) on investments of $(20.8) million and $(49.7) million, respectively. As of March 31, 2026 and September 30, 2025, our net unrealized appreciation (depreciation) on investments totaled $(66.1) million and $(46.1) million, respectively. The net change in unrealized appreciation (depreciation) on our investments was primarily due to the operating performance of the portfolio companies within our portfolio, changes in the capital market conditions of our investments, and realization of investments.

For the three and six months ended March 31, 2026, our Credit Facility had a net change in unrealized appreciation (depreciation) of less than $0.1 million and less than $0.1 million, respectively. For the three and six months ended March 31, 2025, our Credit Facility had a net change in unrealized appreciation (depreciation) of less than $0.1 million and $0.1 million, respectively. As of March 31, 2026 and September 30, 2025, the net unrealized appreciation (depreciation) on the Credit Facility totaled approximately zero and zero, respectively. The net change in net unrealized (appreciation) or depreciation was primarily due to changes in the capital markets.

Net Change in Net Assets Resulting from Operations

For the three and six months ended March 31, 2026, net increase (decrease) in net assets resulting from operations totaled $28.7 million or $0.29 per share and $25.2 million, or $0.25 per share, respectively. For the three and six months ended March 31, 2025, net increase (decrease) in net assets resulting from operations totaled $1.2 million or $0.01 per share and $29.6 million or $0.34 per share, respectively. The net increase or (decrease) from operations for the three and six months ended March 31, 2026, was primarily due to operating performance of our portfolio and changes in capital market conditions of our investments along with change in size and cost yield of our debt portfolio and costs of financing.

LIQUIDITY AND CAPITAL RESOURCES

Our liquidity and capital resources are derived primarily from cash flows from operations, including income earned, proceeds from investment sales and repayments, and proceeds of securities offerings and debt financings. Our primary use of funds from operations includes investments in portfolio companies and payments of fees and other operating expenses we incur. We have used, and expect to continue to use, our debt capital, proceeds from our portfolio and proceeds from public and private offerings of securities to finance our investment objectives and operations.

In February 2026, the Company closed the refinancing of the 2036 Asset-Backed Debt with a four-year reinvestment period and 12-year final maturity $356.5 million debt securitization (the "2038-R Asset-Backed Debt"). The Company retained the $69.5 million of the securitization's subordinated notes. The replacement debt had weighted average interest rate of 5.3% as of March 31, 2026 and matures in April 2038.

In March 2026, we issued $200.0 million in aggregate principal amount of 6.75% unsecured 2029 Notes. The effective interest rate on the 2029 Notes is 7.00% and they mature in March 2029.

For the six months ended March 31, 2026 and 2025, the annualized weighted average cost of debt, inclusive of the fee on the undrawn commitment on the Credit Facility, amendment costs and debt issuance costs, was 6.1% and 6.8%, respectively. As of March 31, 2026 and September 30, 2025 we had $439.7 million and $34.1 million of unused borrowing capacity under the Credit Facility, respectively, subject to leverage and borrowing base restrictions.

As of March 31, 2026 and September 30, 2025, we had cash and cash equivalents of $121.9 million and $122.7 million, respectively, available for investing and general corporate purposes. We believe our liquidity and capital resources are sufficient to take advantage of market opportunities.

During the three and six months ended March 31, 2026, we did not issue any shares of our common stock under the ATM Programs. During the three and six months ended March 31, 2025, we issued 11,562,000 shares and 18,838,000 shares of our common stock under the ATM Programs, respectively, at an average price of $11.34 per share and $11.35 per share raising $131.0 million and
$213.2 million of net proceeds after commissions to the Sales Agents and inclusive of proceeds from the Investment Adviser to ensure that all shares were sold at or above NAV, respectively.

For the six months ended March 31, 2026, our operating activities provided cash of $172.9 million and our financing activities used cash of $173.7 million. Our operating activities provided cash primarily due to our investment activities and our financing activities used cash primarily due to repayments of our Credit Facility offset by proceeds received from the sales of $28.5 million of 2037 Class D Notes, $21.0 million of 2036-R Asset-Backed Debt D-R Notes to third parties and the issuance of $200.0 million of our 2029 Notes.

For the six months ended March 31, 2025, our operating activities used cash of $350.8 million and our financing activities provided cash of $350.1 million. Our operating activities used cash primarily due to our investment activities and our financing activities provided cash primarily due to borrowings under our Credit Facility, proceeds from the 2037 Asset-Backed debt and proceeds from the public offerings under our 2024 ATM Program.

DISTRIBUTIONS

During the three and six months ended March 31, 2026 we declared distributions of $0.3075 per share and $0.615 per share for total distributions of $30.5 million and $61.0 million. During the three and six months ended March 31, 2025, we declared distributions of $0.3075 per share and $0.615 per share for total distributions of $27.7 million and $52.9 million. We monitor available net investment income to determine if a return of capital for tax purposes may occur for the fiscal year. To the extent our taxable earnings fall below the total amount of our distributions for any given fiscal year, stockholders will be notified of the portion of those distributions deemed to be a tax return of capital. Tax characteristics of all distributions will be reported to stockholders subject to information reporting on Form 1099-DIV after the end of each calendar year and in our periodic reports filed with the SEC.

ADJUSTED DISTRIBUTION POLICY

Given the lower interest rate environment and current market activity levels, in consultation with the Board, we will be adjusting our dividend policy to be better aligned with NII, starting with the July monthly distribution. The monthly base dividend will be adjusted to $0.08 per share. In addition to the base dividend, we plan to pay a monthly supplemental dividend. The supplemental dividend will be variable and, in general, calculated as 50% of prior quarter's NII in excess of the base dividend, if any, rounded to the nearest penny. Such amount will be paid each quarter ratably over a three-month period to be paid at the same time as the base dividend. The exact amount of each supplemental dividend will be included in our monthly distribution announcements. The supplemental dividend for July, August, and September will be $0.0033 per share each month. 

RECENT DEVELOPMENTS

The 2026 Notes were repaid in full on April 1, 2026.

AVAILABLE INFORMATION

The Company makes available on its website its Quarterly Report on Form 10-Q filed with the SEC, and stockholders may find such report on its website at www.pennantpark.com.

 PENNANTPARK FLOATING RATE CAPITAL LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES
(in thousands, except per share data)  March 31, 2026  September 30, 2025 Assets(unaudited)    Investments at fair value   Non-controlled, non-affiliated investments (amortized cost— $2,151,925 and $2,458,018, respectively)$2,189,011  $2,491,360 Controlled, affiliated investments (amortized cost— $494,500 and $361,375, respectively) 391,270   281,968 Total investments (amortized cost— $2,646,425 and $2,819,393, respectively) 2,580,281   2,773,328 Cash equivalents (cost— $31,427 and $40,729, respectively) 31,427   40,729 Cash (cost— $90,446 and $81,955, respectively) 90,444   81,959 Interest receivable 12,611   13,832 Distributions receivable 900   — Receivable for investments sold 30,052   1,369 Due from affiliate 136   321 Prepaid expenses and other assets 2,085   2,143 Total assets 2,747,936   2,913,681 Liabilities   Credit Facility payable, at fair value (cost— $328,355 and $683,855, respectively) 328,333   683,837 2026 Notes payable, net (par—$185,000) (unamortized deferred financing costs of $2 and $391, respectively) 184,998   184,609 2029 Notes payable, net (par—$200,000 and $0) (unamortized deferred financing costs of $4,132 and $0, respectively) 195,868   — 2036 Asset-Backed Debt, net (par—$0 and $287,000) (unamortized deferred financing costs of $0 and $2,373, respectively) —   284,627 2036-R Asset-Backed Debt, net (par— $287,000 and $266,000) (unamortized deferred financing costs of $415 and $634, respectively) 286,585   265,366 2037 Asset-Backed Debt, net (par— $389,500 and $361,000) (unamortized deferred financing costs of $2,355 and $2,669, respectively) 387,145   358,331 2038-R Asset-Backed Debt, net (par—$287,000 and $0) (unamortized deferred financing costs of $2,230 and $0, respectively) 284,770   — Payable for investments purchased —   14,852 Interest payable on debt 15,407   19,172 Distributions payable 10,170   10,170 Base management fee payable 6,427   6,549 Incentive fee payable 6,437   6,883 Accounts payable and accrued expenses 1,581   2,166 Deferred tax liability 1,558   1,864 Due to affiliates —   739 Total liabilities 1,709,279   1,839,165 Net assets   Common stock, 99,217,896 and 99,217,896 shares issued and outstanding, respectively Par value $0.001 per share and 200,000,000 shares authorized 99   99 Paid-in capital in excess of par value 1,219,502   1,219,502 Accumulated deficit (180,944)  (145,085)Total net assets$1,038,657  $1,074,516 Total liabilities and net assets$2,747,936  $2,913,681 Net asset value per share$10.47  $10.83   PENNANTPARK FLOATING RATE CAPITAL LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(Unaudited)   Three Months Ended March 31, Six Months Ended March 31,Investment income: 2026   2025   2026   2025 From non-controlled, non-affiliated investments:       Interest$50,735  $49,215  $107,265  $96,678 Dividend 33   369   41   946 Other income 386   634   1,148   2,114 From controlled, affiliated investments:Interest 8,652   7,345   16,497   20,153 Dividend 6,150   4,375   11,094   8,750 Other income —   —   —   306 Total investment income 65,956   61,938   136,045   128,947 Expenses:Interest and expenses on debt 24,139   22,529   51,293   44,890 Performance-based incentive fee 6,437   6,258   13,097   13,750 Base management fee 6,427   5,604   13,241   10,868 General and administrative expenses 1,200   1,200   2,400   2,400 Administrative services expenses 900   650   1,800   1,150 Expenses before amendment costs, debt issuance costs and provision for taxes 39,103   36,241   81,831   73,058 Provision for taxes on net investment income 25   225   250   450 Credit Facility amendment and debt issuance costs 1,080   442   1,578   442 Total expenses 40,208   36,908   83,659   73,950 Net investment income 25,748   25,030   52,386   54,997 Realized and unrealized gain (loss) on investments and debt:       Net realized gain (loss) on:       Non-controlled, non-affiliated investments (7,535)  (795)  (6,079)  386 Non-controlled and controlled, affiliated investments —   (2,682)  —   22,811 Provision for taxes on realized gain (loss) on investments —   (21)  —   (94)Debt extinguishment (1,380)  —   (1,380)  — Net realized gain (loss) on investments (8,915)  (3,498)  (7,459)  23,103 Net change in unrealized appreciation (depreciation) on:Non-controlled, non-affiliated investments 25,010   (9,630)  3,744   (6,688)Controlled and non-controlled, affiliated investments (12,802)  (11,146)  (23,823)  (43,050)Provision for taxes on unrealized appreciation (depreciation) on investments (329)  468   307   1,100 Debt appreciation (depreciation) 26   1   4   91 Net change in unrealized appreciation (depreciation) on investments and debt 11,905   (20,307)  (19,768)  (48,547)Net realized and unrealized gain (loss) from investments and debt 2,990   (23,805)  (27,227)  (25,444)Net increase (decrease) in net assets resulting from operations$28,738  $1,225  $25,159  $29,553 Net increase (decrease) in net assets resulting from operations per common share$0.29  $0.01  $0.25  $0.34 Net investment income per common share$0.26  $0.28  $0.53  $0.64                  ABOUT PENNANTPARK FLOATING RATE CAPITAL LTD.

PennantPark Floating Rate Capital Ltd. is a business development company which primarily invests in U.S. middle-market companies in the form of floating rate senior secured loans, including first lien secured debt, second lien secured debt and subordinated debt. From time to time, the Company may also invest in equity investments. PennantPark Floating Rate Capital Ltd. is managed by PennantPark Investment Advisers, LLC.

ABOUT PENNANTPARK INVESTMENT ADVISERS, LLC

PennantPark Investment Advisers, LLC, a leading middle-market credit platform, and its affiliates, manage approximately $10 billion of investable capital, including potential leverage. Since its inception in 2007, PennantPark Investment Advisers, LLC has provided investors access to middle-market credit by offering private equity firms and their portfolio companies as well as other middle-market borrowers a comprehensive range of creative and flexible financing solutions. PennantPark Investment Advisers, LLC is headquartered in Miami and has offices in New York, Chicago, Houston, Los Angeles, Amsterdam, and Zurich. For more information about PennantPark and affiliates, please go to our website at www.pennantpark.com.

FORWARD-LOOKING STATEMENTS AND OTHER

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. You should understand that under Section 27A(b)(2)(B) of the Securities Act of 1933, as amended, and Section 21E(b)(2)(B) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 do not apply to forward-looking statements made in periodic reports we file under the Exchange Act. All statements other than statements of historical facts included in this press release are forward-looking statements and are not guarantees of future performance or results, and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in filings with the Securities and Exchange Commission. PennantPark Floating Rate Capital Ltd. undertakes no duty to update any forward-looking statement made herein. You should not place undue influence on such forward-looking statements as such statements speak only as of the date on which they are made.

We may use words such as “anticipates,” “believes,” “expects,” “intends,” “seeks,” “plans,” “estimates” and similar expressions to identify forward-looking statements. Such statements are based on currently available operating, financial and competitive information and are subject to various risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations.

The information contained herein is based on current tax laws, which may change in the future. The Company cannot be held responsible for any direct or incidental loss resulting from applying any of the information provided in this publication or from any other source mentioned. The information provided in this material does not constitute any specific legal, tax or accounting advice. Please consult with qualified professionals for this type of advice.

CONTACT: Richard T. Allorto, Jr.
PennantPark Floating Rate Capital Ltd.
(212) 905-1000
www.pennantpark.com

PennantPark Floating Rate Capital (PFLT) Q2 2026 Earnings Call Transcript

PennantPark Floating Rate Capital remains a hold as NAV declines and flat earnings persist, despite a 13.8% dividend yield. PFLT will reduce its monthly payout to $0.08 per share in July, aligning distributions with net investment income and improving future dividend coverage. Negative net investment activity and rising debt-to-equity (1.61x) highlight limited near-term growth catalysts and ongoing portfolio challenges.

In the article I list all monthly-paying BDCs. This list is then reduced to a handful of BDCs. These remaining BDCs, in my view, are the one with the strongest prospect to generate durable income without permanent NAV decay.

© Adansijav Official / Shutterstock.com

For income investors hunting yield in a choppy rate environment, business development companies (BDCs) trading under $30 deserve a fresh look. These middle-market lenders pass through interest income as eye-watering distributions, and several names in the group now sit well off their highs after a year of yield compression and dividend resets. That combination, depressed share prices alongside double-digit yields, is exactly where opportunistic income buyers like to hunt.

With that in mind, here is one ultra-high-yield BDC trading under $30 that looks compelling right now, anchored by a 100% floating-rate portfolio and a fresh joint venture set to recharge earnings.

PennantPark Floating Rate Capital (NYSE: PFLT) PennantPark Floating Rate Capital (NYSE:PFLT) is a business development company that provides floating-rate loans to middle-market enterprises, with capital preservation as a stated priority.

Shares closed the most recent session at $8.33, a level that puts the stock comfortably in retail-accessible territory and well below its 52-week high of $9.72. For a retail investor, that low absolute price means a $1,000 allocation buys a meaningful share count, amplifying the dollar value of every monthly distribution.

The fundamentals tell a value story. PFLT trades at a price-to-book ratio of 0.784 against a book value of $10.49 per share, meaning buyers are paying roughly 78 cents for every dollar of net asset value. The trailing P/E sits at 13, dropping to 11 on a forward basis. Wall Street is constructive: the analyst target price of $10.08 implies meaningful upside, and the rating mix of three Strong Buys, two Buys, and two Holds leans positive with no sell ratings.

The bull case rests on three pillars. First, the dividend. The current monthly base of $0.1025 annualizes to $1.23 per share for a yield around 15%, and even after a planned reset to $0.08 monthly plus a $0.0033 supplemental starting July 2026, the payout still clears double digits at current prices. Second, the portfolio. CEO Art Penn noted that “NAV was flat for the quarter and portfolio company leverage, PIK interest and non accruals are among the lowest in the industry”, with PIK interest at 1.8% and non-accruals at 0.8% of portfolio at cost. Third, the growth engine: the PSSL II joint venture with Hamilton Lane scaled to $339.9 million in the latest quarter and is designed to drive net investment income higher as it ramps toward a $500 million target portfolio. With 100% of the debt portfolio in floating-rate instruments, sustained higher rates or sticky inflation feed directly into net investment income.

The key risk cuts against the income narrative directly. The looming dividend reset reflects yield compression, with the weighted average yield on debt sliding from 10.2% to 9.8%, and Q2 NII of $0.26 missed the $0.28 estimate. Net unrealized depreciation of $66.1 million on the portfolio is a reminder that mark-to-market risk is real. Still, the discount to NAV, the floating-rate posture, and the JV ramp argue that the reset is already in the price.

For income-focused investors comfortable with BDC volatility, PFLT screens as a deep-value setup, trading at a steep NAV discount with a double-digit yield that appears covered by net investment income.

The Bottom Line A sub-$10 share price alone is never a reason to buy, and a high yield is never a guarantee of safety. BDC distributions track net investment income, which moves with credit spreads, base rates, and non-accruals. Investors should pair this thesis with their own work on portfolio quality, leverage, and rate sensitivity before sizing any position.

PennantPark Floating Rate Capital has issued its first listed fixed-income security, the 7.375% Notes due 2031, currently priced at par. PFLT's asset coverage ratio stands at 162% but could fall to 158% if all PFLA proceeds are invested in new assets, still above the regulatory 150% requirement. Recent dividend cuts and a decrease in the asset coverage ratio suggest caution for creditors, as coverage has tightened; NAV per share has also shown gradual depletion.

OMAHA, Neb. & DAR ES SALAAM, Tanzania--(BUSINESS WIRE)--ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology, today announced the extension of its long-standing partnership with UBX Tanzania Limited, Tanzania's leading national payment service provider. The extended partnership marks a significant milestone in a relationship that spans nearly two decades and is focused on strengthening infrastructure resilience, enhancing scalability and enabling innovation to suppo.

April 06, 2026 08:00 ET  | Source: Geron Corporation

FOSTER CITY, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 11:00 a.m. ET.

A live and archived audio webcast of the fireside chat will be available through the Investors & Media section of Geron’s website at www.geron.com.

About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.

Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
[email protected]

April 14, 2026 16:05 ET  | Source: Geron Corporation

FOSTER CITY, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a stock option to purchase 2,500,000 shares of Geron common stock to Timothy Williams, Geron’s new Executive Vice President, Chief Legal Officer and Corporate Secretary, as an inducement material to his acceptance of employment with Geron.

The stock option was granted on April 13, 2026. The stock option has an exercise price of $1.73 per share, which is equal to the closing price of Geron’s common stock on the grant date, has a ten-year term and vests over four years, with 12.5% of the shares underlying the option vesting on the six-month anniversary of commencement of his employment and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued service with Geron through the applicable vesting dates.

The stock option grant was approved by the Compensation Committee of Geron’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and is subject to the terms and conditions of Geron’s 2018 Inducement Award Plan and the form of stock option agreement under that plan.

About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.

CONTACT:
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
[email protected]

April 20, 2026 16:05 ET  | Source: Geron Corporation

FOSTER CITY, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective April 17, 2026, it granted stock options to purchase an aggregate of 855,000 shares of common stock to nine newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.

The stock options have an exercise price of $1.68 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.

The equity awards were granted by the Compensation Committee of Geron’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of Geron’s 2018 Inducement Award Plan and the form of stock option agreement under the plan.

About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.

CONTACT:
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
[email protected]

May 05, 2026 08:00 ET  | Source: Geron Corporation

FOSTER CITY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following investor conferences:

Bank of America Securities 2026 Healthcare Conference
Presentation on Tuesday, May 12 at 4:35 p.m. ET in Las Vegas, NV 2026 Stifel Virtual Targeted Oncology Forum
Virtual presentation on Wednesday, May 20 at 12:00 p.m. ET A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company’s website at www.geron.com.

About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.

Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
[email protected]

Geron (GERN - Free Report) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +60.00%. A quarter ago, it was expected that this drugmaker would post a loss of $0.03 per share when it actually produced a loss of $0.03, delivering no surprise.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Geron, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $51.84 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 2.94%. This compares to year-ago revenues of $39.6 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Geron shares have added about 25% since the beginning of the year versus the S&P 500's gain of 6%.

What's Next for Geron?While Geron has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Geron was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.01 on $54.18 million in revenues for the coming quarter and -$0.05 on $227.94 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Biorestorative Therapies, Inc. (BRTX - Free Report) , has yet to report results for the quarter ended March 2026.

This company is expected to post quarterly loss of $0.30 per share in its upcoming report, which represents a year-over-year change of +46.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Biorestorative Therapies, Inc.'s revenues are expected to be $0.05 million, up 66.7% from the year-ago quarter.

May 12, 2026 09:31 ET  | Source: Geron Corporation

Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population 

Additional presentations at EHA 2026 and ASCO 2026 include abstracts related to ongoing myelofibrosis and AML clinical programs

FOSTER CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the first real-world evidence study of RYTELO® (imetelstat) in patients with lower-risk myelodysplastic syndromes (LR-MDS) will be presented at the European Hematology Association (EHA) 2026 Congress. The retrospective and prospective investigator-sponsored study, conducted at the Moffitt Cancer Center, reported safety and clinical efficacy of imetelstat in advanced, heavily transfusion dependent patients with LR-MDS, including patients with extensive prior therapies and after luspatercept failure. Data from the retrospective portion of the study will be presented at the EHA 2026 Congress.

“Imetelstat has become an important treatment option for patients with lower-risk myelodysplastic syndromes experiencing anemia and red blood cell transfusion burden, particularly in patients previously treated with ESAs or other therapies,” said David A. Sallman, M.D., Associate Member, Malignant Hematology Department, Moffitt Cancer Center. “As treatment sequencing has emerged as an increasing area of focus in LR-MDS, real-world analyses such as this study can help provide additional context on how therapies are being used in routine clinical practice and across more diverse patient populations. We look forward to presenting these data at EHA 2026.”

“This is the first real-world study evaluating imetelstat in lower-risk MDS, and we are encouraged that the efficacy, safety and tolerability observed were generally consistent with findings from the Phase 3 IMerge trial in a broader patient population with a trend towards more optimal management of cytopenias,” said Joseph E. Eid, M.D., Executive Vice President, Research and Development and Chief Medical Officer of Geron. “These findings add to the growing body of evidence supporting the use of imetelstat as a preferred treatment option following prior therapy for patients with lower-risk MDS and significant transfusion burden. We look forward to presenting data from the prospective portion of this study later this year.”

The data, from the retrospective portion of the investigator-sponsored study, evaluated imetelstat in 40 patients with lower-risk MDS treated at the Moffitt Cancer Center in a real-world setting following U.S. Food and Drug Administration (FDA) approval. Patients included in the analysis had advanced, heavily transfusion-dependent disease and extensive prior treatment exposure, including prior luspatercept, erythropoiesis-stimulating agents (ESAs), hypomethylating agents and lenalidomide. With 14-month follow-up, the analysis reported a red blood cell (RBC) transfusion independence rate of 37.5% lasting at least eight weeks (RBC-TI > 8 weeks) with several responses ongoing at the time of analysis and identified potential predictors of response. The safety profile observed in the study was generally consistent with the known safety profile of imetelstat. Cytopenias were reported as the most common Grade 3/4 adverse event. Exploratory analyses also suggested a trend toward improved responses when imetelstat was used within the first three lines of therapy.

Geron will also have additional presentations at the EHA 2026 Congress and the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, including abstracts related to its ongoing myelofibrosis clinical programs. This includes an updated overall survival analysis in patients with myelofibrosis treated with imetelstat in the Phase 2 IMbark trial compared with real-world data.

Additional Presentations EHA and ASCO include:

EHA 2026 Presentations

Presentation TitleAuthorAbstract NumberPresentation DetailsReal-world Outcomes of Imetelstat: Interrogating Safety, Efficacy and Predictors of Response in Heavily Pretreated Lower-Risk MDS Patients*David A. Sallman, M.D.#PF670Poster, Jun 12, 18:45-19:45 CESTUpdated Analysis of Overall Survival with Imetelstat in Patients with Relapsed or Refractory Myelofibrosis From IMBark Versus Real-world Data, and Assessment of Real-world Treatment PatternsAndrew T. Kuykendall, M.D.#PB3419Publication-onlyPhase 1/1B Trial of Imetelstat and Azacitadine with or without Venetoclax in Relapsed Acute Myeloid Leukemia (IMAGINE Trial)*Douglas A. Tremblay, M.D.#PB2719Publication-only
*Investigator-sponsored Research (ISR)

ASCO 2026 Presentations

Presentation TitleAuthorAbstract NumberPresentation DetailsUpdated analysis of overall survival with imetelstat in relapsed/refractory myelofibrosis versus real-world data, and assessment of real-world treatment patternsAndrew T. Kuykendall, M.D.#366Poster, Mon. June 1, 9:00 am -12:00 pm CDTUpdated protocol: IMproveMF, a Phase 1b trial of imetelstat + ruxolitinib in patients with intermediate-1/2 or high-risk myelofibrosisJohn O. Mascarenhas, M.D.#394bPoster, Mon. June 1, 9:00 am -12:00 pm CDT
Please see the full presentations for important qualifications and limitations.

About RYTELO (imetelstat)
RYTELO is an oligonucleotide telomerase inhibitor approved in the U.S. for the treatment of adult patients with LR-MDS with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). It is indicated to be administered as an intravenous infusion over two hours every four weeks.

In addition, RYTELO is approved in the European Union as a monotherapy for the treatment of adult patients with transfusion-dependent anemia due to very low, low or intermediate risk myelodysplastic syndromes without an isolated deletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.

RYTELO is a first-in-class treatment that works by inhibiting telomerase enzymatic activity. Telomeres are protective caps at the end of chromosomes that naturally shorten each time a cell divides. In LR-MDS, abnormal bone marrow cells often express the enzyme telomerase, which rebuilds those telomeres, allowing for uncontrolled cell division. Developed and exclusively owned by Geron, RYTELO is the first and only telomerase inhibitor approved by the U.S. Food and Drug Administration and the European Commission.

About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with LR-MDS with transfusion-dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor R/R MF, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or LinkedIn.

US IMPORTANT SAFETY INFORMATION ABOUT RYTELO®
WARNINGS AND PRECAUTIONS

Thrombocytopenia
RYTELO can cause thrombocytopenia based on laboratory values. In the clinical trial, new or worsening Grade 3 or 4 decreased platelets occurred in 65% of patients with MDS treated with RYTELO.

Monitor patients with thrombocytopenia for bleeding. Monitor complete blood cell counts prior to initiation of RYTELO, weekly for the first two cycles, prior to each cycle thereafter, and as clinically indicated. Administer platelet transfusions as appropriate. Delay the next cycle and resume at the same or reduced dose, or discontinue as recommended.

Neutropenia
RYTELO can cause neutropenia based on laboratory values. In the clinical trial, new or worsening Grade 3 or 4 decreased neutrophils occurred in 72% of patients with MDS treated with RYTELO.

Monitor patients with Grade 3 or 4 neutropenia for infections, including sepsis. Monitor complete blood cell counts prior to initiation of RYTELO, weekly for the first two cycles, prior to each cycle thereafter, and as clinically indicated. Administer growth factors and anti-infective therapies for treatment or prophylaxis as appropriate. Delay the next cycle and resume at the same or reduced dose, or discontinue as recommended.

Infusion-Related Reactions
RYTELO can cause infusion-related reactions. In the clinical trial, infusion-related reactions occurred in 8% of patients with MDS treated with RYTELO; Grade 3 or 4 infusion-related reactions occurred in 1.7%, including hypertensive crisis (0.8%). The most common infusion-related reaction was headache (4.2%). Infusion-related reactions usually occur during or shortly after the end of the infusion.

Premedicate patients at least 30 minutes prior to infusion with diphenhydramine and hydrocortisone as recommended and monitor patients for at least one hour following the infusion as recommended. Manage symptoms of infusion-related reactions with supportive care and infusion interruptions, decrease infusion rate, or permanently discontinue as recommended.

Embryo-Fetal Toxicity
Based on animal findings, RYTELO can cause embryo-fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with RYTELO and for 1 week after the last dose.

ADVERSE REACTIONS
Serious adverse reactions occurred in 32% of patients who received RYTELO. Serious adverse reactions in >2% of patients included sepsis (4.2%) and fracture (3.4%), cardiac failure (2.5%), and hemorrhage (2.5%). Fatal adverse reactions occurred in 0.8% of patients who received RYTELO, including sepsis (0.8%).

Most common adverse reactions (≥10% with a difference between arms of >5% compared to placebo), including laboratory abnormalities, were decreased platelets, decreased white blood cells, decreased neutrophils, increased AST, increased alkaline phosphatase, increased ALT, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-19 infections, and headache.

Please see RYTELO (imetelstat) full Prescribing Information, including Medication Guide, available at https://pi.geron.com/products/US/pi/rytelo_pi.pdf.

The Summary of Product Characteristics (SmPC) for RYTELO in the EU is available at https://pi.geron.com/products/rytelo/eu/rytelo_smpc_eu.pdf

Use of Forward-Looking Statements
Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such statements, include, without limitation, those regarding: (i) the potential of real-world analyses to provide additional context on how therapies such as RYTELO are being used in routine clinical practice and across more diverse patient populations; (ii) Geron’s efforts to expand its understanding of RYTELO in clinical practice; (iii) Geron’s expectations for multiple analyses emerging from investigator-sponsored research which will complement clinical trial data and help inform treatment decisions for people living with LR-MDS; (iv) the potential for telomerase inhibition to reduce proliferation and induce death of malignant cells; and (v) other statements that are not historical facts, constitute forward-looking statements. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties, include, without limitation, risks and uncertainties related to: (a) Geron’s future opportunities and plans, including the uncertainty of the nature of, and the timing and reporting of data emerging from, investigator-sponsored and real-world evidence trials of RYTELO; (b) whether Geron overcomes potential delays and other adverse impacts that may be caused by enrollment, clinical, safety, efficacy, technical, scientific, intellectual property, manufacturing, supply chain, pricing, coverage and reimbursement, market penetration, regulatory and healthcare challenges in order to obtain and maintain the financial resources for and meet expected timelines and planned milestones, including the financial resources necessary to support investigator-sponsored research of RYTELO; (c) Geron’s reliance on investigator-sponsored research, including risks related to Geron’s lack of control over such investigator-sponsored research of RYTELO and the risk that investigator-led clinical trials over which Geron has no control could show marginal efficacy and/or clinically relevant safety concerns that could delay, limit or preclude the further clinical development, marketing approval and/or commercialization of RYTELO in any indication; (d) whether regulatory authorities permit the further development of imetelstat on a timely basis, or at all, without any clinical holds; (e) whether any future safety or efficacy results of RYTELO treatment cause its benefit-risk profile to become unacceptable; (f) whether imetelstat actually demonstrates disease-modifying activity in patients, including transfusion independence in LR-MDS, and the ability to target the malignant stem and progenitor cells of the underlying disease; (g) whether Geron meets its post-marketing requirements and commitments for RYTELO; and (h) whether there are failures or delays in manufacturing or supplying sufficient quantities of RYTELO (imetelstat) or other clinical trial materials that negatively impact the conduct and timing of clinical trials. Additional information on the above risks and uncertainties and additional risks, uncertainties and factors that could cause actual results to differ materially from those in the forward-looking statements are contained in Geron’s filings and periodic reports filed with the Securities and Exchange Commission under the heading “Risk Factors” and elsewhere in such filings and reports, including Geron’s quarterly report on Form 10-Q for the quarter ended March 31, 2026, and subsequent filings and reports by Geron. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying the forward-looking statements may change. Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances.

Investor and Media:
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
[email protected]

May 18, 2026 16:01 ET  | Source: Geron Corporation

FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock options to purchase an aggregate of 333,750 shares of common stock to five newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.

The stock options have an exercise price of $1.29 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.

The equity awards were granted by the Compensation Committee of Geron’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of Geron’s 2018 Inducement Award Plan and the form of stock option agreement under the plan.

About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.

CONTACT:
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
[email protected]

Geron has secured FDA approval for RYTELO in low- to intermediate-1 risk MDS, marking a pivotal milestone after decades of development. Despite disappointing initial RYTELO sales, GERN forecasts 2026 revenues of $220–$240 million and is executing targeted commercial and European expansion strategies. A new management team is in place, with significant liquidity ($341 million) and a cash runway of ~2.7 years supporting ongoing pipeline and commercial efforts.

Geron (GERN - Free Report) has been beaten down lately with too much selling pressure. While the stock has lost 26.6% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.

We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.

RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.

Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.

So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefiting from the inevitable rebound.

However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.

Why a Trend Reversal is Due for GERNThe heavy selling of GERN shares appears to be in the process of exhausting itself, as indicated by its RSI reading of 26.52. So, the trend for the stock could reverse soon for reaching the old equilibrium of supply and demand.

The RSI value is not the only factor that indicates a potential turnaround for the stock in the near term. On the fundamental side, there has been strong agreement among the sell-side analysts covering the stock in raising earnings estimates for the current year. Over the last 30 days, the consensus EPS estimate for GERN has increased 55.6%. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.

Moreover, GERN currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .